Longidase is a complex of macromolecules entering the proteolytic enzyme of hyaluronidase and having a high molecular weight carrier. The carrier is an element from the category of N-hydroxy-poly-1,4-ethylene piperazine derivatives. Longidazu is distinguished by the powerful activity of hyaluronidase (it is several times higher than the activity of native-type hyaluronidase), which develops because the conjugate is more resistant to the effects of slowing components, as well as temperatures.
The drug has powerful anti-inflammatory, immunostimulating, anti-edema, antioxidant, and also chelating properties. Hyaluronidase contains specific substrates, which are glycosaminoglycans - the elements of connective tissues, among which chondroitin-4-sulfate, as well as chondroitin-6-sulfate, and in addition hyaluronan with chondroitin. The glycolysis process makes it possible to reduce the viscosity of glycosaminoglycans and, at the same time, the ability to synthesize metal ions with water. As a result, tissue trophism and permeability increase, resorption with hematomas and a reduction in the swelling, and in addition, the elasticity of the areas on which the scars are located improves. The glycolysis of these elements also allows to reduce the severity or completely remove the limited joint mobility and adhesions.
The most effective medicine will be in case of its use at the initial stages of treatment of the disease.
The antioxidant property of Longidase is ensured by the ability of the active ingredient to synthesize iron ions. These substances activate the response of free radicals, and in addition stimulate the processes of collagen binding and slowing down of hyaluronidase.
The pronounced antifibrotic effect of the drug is proved by a multitude of biochemical, electron microscopic, and histological tests performed on a sample of pneumofibrosis.
Suppositories normalize the process of synthesis of inflammation conductors, promote the strengthening of humoral immunity, and at the same time reduce the intensity of manifestations of inflammation during the acute stage of the disease.
The drug can be used to prevent the development of adhesions or scars after surgery, because it does not have a negative effect on the course of the postoperative period and does not provoke the progression of the infection. In addition, it does not interfere with the restorative process inside bone tissues.
Through the use of drugs, the level of bioavailability of other drugs increases, and with it the development of the effect of the use of local anesthetics is accelerated.
Longidase has a weak toxicity, the active substance of the drug does not affect the functioning of the immune and reproductive systems. It has no mutagenic, carcinogenic, and teratogenic properties.